

“

I've been severely depressed since childhood and have had thoughts of suicide many times. My outpatient therapist suggested GRAND Infusion, and after just 7 treatments, I'm feeling so much better.

– Tosha N.

”

GRAND Infusion Center - Tulsa

Skyline East II
5th Floor
6128 E 38th Street
Tulsa, OK 74135

539.593.5382

grandinfusioncenter@grandmh.com



The Next Step In Accessible Mental Health Treatment Is Here.



HOW IT WORKS.

Utilizing FDA approved Spravato (Esketamine), GRAND Infusion Center clients self-administer treatments through a simple intra-nasal spray under the supervision of a licensed health care provider in our certified clinic.

Clients remain under observation for approximately two hours in the clinic. This observation time is crucial as the immediate side effects can include a distortion of an individual's perception.

Within these two hours, the disorientation significantly decreases and patients often describe increased calm and less distress from their depression.

For some patients, there is a significant and immediate decrease in depressive symptoms.



WHAT IS THE GRAND INFUSION CENTER?

The GRAND Infusion Center offers the latest, FDA approved treatment for Treatment Resistant Major Depressive Disorder (TRD).

Recent studies suggest that 2 in 10 Americans suffer from depression and 30% of those are diagnosed with Treatment-Resistant Depression (TRD). For those with TRD, life can be overwhelming, at times even suicidal thoughts or actions occur.

The GRAND Infusion Center was designed to meet the needs of Oklahomans suffering from TRD.

MORE ABOUT ESKETAMINE/ SPRAVATO.™

Esketamine is a treatment that can shift how the brain works and how the brain communicates with the body.

Esketamine affects depressive symptoms by targeting different neural receptors in the brain to increase brain plasticity. Brain plasticity is when the neural networks change, grow and reorganize.

Most antidepressants work on specific chemicals in the brain such as serotonin and dopamine. Esketamine works on another kind of chemical called glutamate.

Glutamate is the most abundant chemical messenger within the brain and Esketamine has a larger and faster effect due to this, which is why many patients experience immediate relief.

Spravato™ is a product of Johnson & Johnson Pharmaceutical and was approved by the FDA over 3 years ago.

Spravato is the only FDA approved nasal spray for the treatment of TRD and for suicidal ideation associated with MDD.

According to recent J&J data, 27.1% of Spravato patients experienced remission at eight weeks. Further, remission rates for patients on Spravato continued to increase after that time, with 55% in remission at 32 weeks.

MORE ABOUT THE GRAND TEAM.

K. Michael Saliba, MD

Naomi Walcott, RN

Mary James, Team Support Specialist



The GRAND Infusion Center operates under the leadership of Psychiatrist Kahlil Michael Saliba, MD.

Dr. Saliba earned his medical degree from

American University of Beirut followed by residency at The University of Iowa with a fellowship in child and adolescent psychiatry. He practiced psychiatry at Laureate St. Francis for over 10 years, later serving as the Medical Director of Shadow Mountain Hospital. Double board certified with the American Board of Psychiatry and Neurology for both General psychiatry and Child and Adolescent psychiatry, Dr. Saliba's extensive experience with ADHD and mood disorders such as depression and bipolar disorders provides GRAND an invaluable asset to patient care.

Collectively, our GRAND Infusion Center treatment team has over 25 years of experience in the medical field, with specialized experience in the area of Treatment Resistant Major Depressive Disorder, including Ketamine treatment. The team played a vital role in the state of Oklahoma's Spravato launch, after FDA approval in March 2019.